This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a $855m offer for rare disease company Wilson Therapeutics. ... Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a
Arcturus Therapeutics. thrombopoietin; alpha-1 antitrypsin replacment; cystic fibrosis; iron disorders. Tekmira, Arrowhead. ... Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
IGEM Therapeutics appoints Dr Tim Wilson as CEO. He joins after the UK immuno-oncology firm raises £2m to advance its pipeline. ... Wilson has over 28 years’experience in the life sciences sector, ranging from venture capital and start-ups to
He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...